• Publications
  • Influence
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2
BackgroundSecukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessedExpand
  • 14
  • 1
AB0685 Secukinumab provides sustained improvements in work productivity and health related quality of life in patients with ankylosing spondylitis: long-term results from measure 1 and measure 2
Background Patients (pts) with ankylosing spondylitis (AS) experience significant restrictions in work productivity and health-related quality of life (HRQoL). Secukinumab (SEC) demonstrated rapidExpand
  • 3
AB0766 Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis (DAPSA): 2 year results from the future 2 study
Background Disease Activity Index for Psoriatic Arthritis (DAPSA) is a validated tool to measure disease activity states, focussing on peripheral joint involvement in psoriatic arthritis (PsA), andExpand
  • 1
FRI0494 Secukinumab provides rapid and sustained pain relief in psoriatic arthritis: 2-year results from the future 2 study
Background Pain remains a major clinical challenge in the treatment of psoriatic arthritis (PsA). Secukinumab (SEC) has demonstrated significant efficacy in PsA patients (pts), across a range ofExpand
  • 1
THU0393 Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through 3 years: long-term results of two randomised double-blind placebo-controlled phase 3 studies
Background In patients (pts) with ankylosing spondylitis (AS), fatigue is a common symptom negatively affecting health-related quality of life (HRQoL) and social functioning. Secukinumab (SEC), aExpand
SAT0480 Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal phase 3 clinical trial data
Background Therapeutic options with discrete modes of action are now available for psoriatic arthritis (PsA). Clinicians require evidence to guide decision-making. No head-to-head RCTs have comparedExpand
AB0765 Secukinumab provides sustained improvement in function, quality of life and fatigue over 2 years in patients who achieved disease activity index for psoriatic arthritis (DAPSA) remission
Background Disease Activity index for Psoriatic Arthritis (DAPSA) states are associated with functional impairment levels in patients (pts) with psoriatic arthritis (PsA).1 Secukinumab demonstratedExpand